KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

15.66 +0.20 (+1.29%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist

Price and Volume

Volume	765,888
Open	15.38
Bid (Size)	15.63 (100)
Ask (Size)	15.65 (1,600)
Prev. Close	15.46
Today's Range	15.12 - 15.70
52wk Range	7.300 - 17.30
Shares Outstanding	34,233,643
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema

December 22, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

These stocks are moving in today's session ↗

December 03, 2025

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Performance

YTD	+1.3%	+1.3%
1 Month	-7.1%	-7.1%
3 Month	+42.9%	+42.9%
6 Month	+4.0%	+4.0%
1 Year	+80.4%	+80.4%

More News

KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results

November 10, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year ↗

September 19, 2025

Via Stocktwits

KalVista Pharma's Earnings: A Preview ↗

September 10, 2025

Via Benzinga

Examining the Future: KalVista Pharma's Earnings Outlook ↗

November 10, 2025

Via Benzinga

KalVista Pharmaceuticals Presents New Data Highlighting Patient Satisfaction with EKTERLY® (sebetralstat) and its Potential in Children Ages 2-11 at the ACAAI 2025 Annual Scientific Meeting

November 06, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

November 05, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

November 03, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

October 30, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Via MarketMinute

KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe

October 06, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

October 06, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

October 02, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress

September 26, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031

September 24, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 24, 2025

Via Benzinga

KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes

September 24, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema

September 19, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

KalVista Posts 154% Expense Jump in Q1 ↗

September 11, 2025

Via The Motley Fool

KalVista Pharmaceuticals Inc (NASDAQ:KALV) Stock Rises 7.4% on Strong EKTERLY Launch Despite Q1 Earnings Miss ↗

September 11, 2025

Via Chartmill

KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Quarter Financial Results

September 11, 2025

From KalVista Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For September 11, 2025 ↗

September 11, 2025

Via Benzinga

KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

September 10, 2025

Via Benzinga

Frequently Asked Questions

Is KalVista Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, KalVista Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does KalVista Pharmaceuticals, Inc. - Common Stock trade on?

KalVista Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for KalVista Pharmaceuticals, Inc. - Common Stock is KALV on the Nasdaq Stock Market

What is the current price of KalVista Pharmaceuticals, Inc. - Common Stock?

The current price of KalVista Pharmaceuticals, Inc. - Common Stock is 15.66

When was KalVista Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of KalVista Pharmaceuticals, Inc. - Common Stock was at 01/05/26 04:00 PM ET

What is the market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock?

The market capitalization of KalVista Pharmaceuticals, Inc. - Common Stock is 536.10M

How many shares of KalVista Pharmaceuticals, Inc. - Common Stock are outstanding?

KalVista Pharmaceuticals, Inc. - Common Stock has 536M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.